SCHEMBL4132822

SCHEMBL4132822

CC(C(=O)O)c1ccc(NC2=NC(=O)/C(=C/c3cc(Br)c(O)c(Br)c3)S2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
POLB P06746 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
RECQL P46063 2/20 0.43
USP2 O75604 1/20 0.43
NSD2 O96028 1/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43
SYK P43405 1/20 0.43
BLM P54132 1/20 0.43
MCL1 Q07820 1/20 0.43
PTGS1 P23219 9/20 0.42
PTGS2 P35354 8/20 0.42
CISD1 Q9NZ45 2/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132825 1.00 MEN1 (0.45) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL4133647 0.77 ALOX5 (0.46) MEN1KMT2AALDH1A1MAPTGAA
SCHEMBL4133650 0.77 ALOX5 (0.46) MEN1KMT2AALDH1A1MAPTGAA
SCHEMBL4141046 0.73 TDP1 (0.36) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL4141047 0.73 TDP1 (0.36) MEN1KMT2AKDM4EMAPTGAA
SCHEMBL4129615 0.72 ALOX5 (0.48) ALOX5
SCHEMBL4129611 0.72 ALOX5 (0.48) ALOX5
SCHEMBL4137074 0.72 ALOX5 (0.36) POLBMAPTCISD1ALOX5
SCHEMBL4133852 0.71 PRMT5 (0.46) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL4133850 0.71 PRMT5 (0.46) MEN1KMT2APOLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MEN1 4075/4885KMT2A 2895/4885POLB 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.